Pre-Survey

Please describe yourself

In which country do you practice?

Does national insurance in your country pay for treatment for anti-VEGF therapy?

How many NEW patients you see each MONTH who have DR/DME?

How would you rate your current knowledge of the PATHWAYS and MECHANISMS involved with DR/DME?

Please rate your agreement with the following statement: “Among anti-VEGF therapies, there is a measurable difference in terms of efficacy, safety, and cost.”

Which single therapy do you prescribe most often for DR/DME?

Bevacizumab

Ranibizumab

Aflibercept

Other

Why do you prescribe this therapy?

9. Which anti-VEGF agent has been shown to bind to all isomers of the VEGF-A family, VEGF-B, and placental growth factor?

For DR/DME, How would you rank your typical patients’ understanding of their disease?

How much time do you personally spend with patients discussing quality of life issues?

Which Quality of life issue do you most commonly discuss with your patients?

Beta version!

Attention!